Assistant Accountant role with listed global Biotech Company

ausbiotech

Immutep Limited is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States with offices in Australia, Germany and France.
We are looking for an Assistant Accountant to be based in our Sydney office.

Job Duties and Responsibilities:

Accounts Payable
Monitoring finance department email inbox
Monthly bank and Company credit card reconciliation
Reconcile balance sheet accounts  and resolve any issues
Reconcile intercompany accounts
Assist with monthly payroll processing
Assist with the month end processing and annual audit/half yearly review
Other accounts and administration tasks as requested
Skills and Attributes:

Tertiary education (or towards completion) in accounting/finance
Experienced in Accounts Payables
Experienced in Account Reconciliations in multiple currencies
Excellent written and oral communication skills
Self-motivated, with a positive mindset, who listens and works well within a team environment
High level of accuracy and attention to detail.
Intermediate Microsoft Office application skills particularly with Excel including formulas ( vlookup, sumifs etc) and pivot table
Minimum 2 years' experience in accounting
Knowledge of NetSuite would be advantageous but not essential
Please note only short listed applicants will be contacted.
This is a permanent, full time position. Located in the Sydney CBD with the ability to work flexibly remotely for the right candidate.
If you are interested in this challenging career opportunity, please submit your CV and application letter via Seek or email any queries to  hr-australia@immutep.com

lynnlee

感谢分享 已投。

ausbiotech

competitive market salary plus equity incentive for the right candidate

ausbiotech

lynnlee 发表于 2022-5-26 15:26
感谢分享 已投。

noted and thanks

ausbiotech

Immutep is global leader in the understanding and development of therapeutics that relate to Lymphocyte Activation Gene-3 or "LAG-3” which is a cell surface molecule that plays a vital role in regulating the immune system. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases.

We have three clinical and one pre-clinical LAG-3 related product candidates under development, including two antibodies for modulating immune responses in cancer and autoimmunity, being advanced through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

ausbiotech

自己顶贴